Access to affordable medicines: obligations of universities and academic medical centers

Steven Joffe^{1

2}, Rena M Conti³, Jorge L Contreras⁴, Emily A Largent^{5

6}, Holly Fernandez Lynch^{5

6}, David Mitchell⁷, Rachel E Sachs⁸, Allison M Whelan⁹, Matthew S McCoy^{5

6}

Affiliations

¹ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. joffes@upenn.edu.
² Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA. joffes@upenn.edu.
³ Department of Markets, Public Policy and Law, Questrom School of Business, Boston University, Boston, MA, USA.
⁴ S.J. Quinney College of Law, University of Utah, Salt Lake City, UT, USA.
⁵ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA.
⁷ Patients for Affordable Drugs, Washington, DC, USA.
⁸ Washington University School of Law, St. Louis, MO, USA.
⁹ Georgia State University College of Law, Atlanta, GA, USA.

Review

Steven Joffe et al. Gene Ther. 2023 Nov.

. 2023 Nov;30(10-11):753-755.

doi: 10.1038/s41434-023-00393-2. Epub 2023 Nov 8.

Steven Joffe^{1

2}, Rena M Conti³, Jorge L Contreras⁴, Emily A Largent^{5

6}, Holly Fernandez Lynch^{5

6}, David Mitchell⁷, Rachel E Sachs⁸, Allison M Whelan⁹, Matthew S McCoy^{5

6}

¹ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. joffes@upenn.edu.
² Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA. joffes@upenn.edu.
³ Department of Markets, Public Policy and Law, Questrom School of Business, Boston University, Boston, MA, USA.
⁴ S.J. Quinney College of Law, University of Utah, Salt Lake City, UT, USA.
⁵ Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁶ Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, PA, USA.
⁷ Patients for Affordable Drugs, Washington, DC, USA.
⁸ Washington University School of Law, St. Louis, MO, USA.
⁹ Georgia State University College of Law, Atlanta, GA, USA.

No abstract available

References

1. Institute for Clinical and Economic Review. Modulator treatments for cystic fibrosis: effectiveness and value. 2020. https://icer.org/wp-content/uploads/2020/08/ICER_CF_Final_Report_092320.pdf . Accessed 7 Jan 2023.
1. Office of Representative Katie Porter. Skyrocketing: how big pharma exploits launch pricest to cash in on cancer. 2020. https://porter.house.gov/uploadedfiles/skyrocketing_-_how_big_pharma_exp... . Accessed 7 Jan 2023.
1. Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14:381–90. - DOI - PubMed
1. Dusetzina SB, Huskamp HA, Rothman RL, Pinheiro LC, Roberts AW, Shah ND, et al. Many Medicare beneficiaries do not fill high-price specialty drug prescriptions. Health Aff. 2022;41:487–96. - DOI
1. Yabroff KR, Dowling EC, Guy GP Jr., Banegas MP, Davidoff A, Han X, et al. Financial hardship associated with cancer in the united states: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34:259–67. - DOI - PubMed